* Kalvista Pharmaceuticals Inc KALV.OQ reported a
quarterly
adjusted loss of 80 cents per share for the quarter ended in
October, higher than the same quarter last year, when the
company reported EPS of -90 cents. The mean expectation of
five analysts for the quarter was for a loss of 79 cents per
share. Wall Street expected results to range from -92 cents
to -66 cents per share.
* Reported revenue was zero; analysts expected zero.
* Kalvista Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 80 cents.
* The company reported a quarterly loss of $27.65 million.
* Kalvista Pharmaceuticals Inc shares had fallen by 6.9%
this
quarter and gained 32.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "buy."
Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $20.00
This summary was machine generated from LSEG data December 7 at
12:45 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Oct. 31 2023 -0.79 -0.80 Missed
Jul. 31 2023 -0.86 -0.74 Beat
Apr. 30 2023 -0.94 -0.77 Beat
Jan. 31 2023 -0.98 -0.75 Beat